clinical trial · NCT03133988
Margetuximab Expanded Access Program
HER2-positive Breast CancerHER2-positive CarcinomaMargetuximab
brief summary
The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.
started
—
primary completion
—
completion
—
last updated
Feb 14, 2025
detailed description
TerSera Therapeutics LLC (TerSera) will consider, on a case-by-case basis, requests by treating physicians to file a single patient investigational new drug application for expanded access to margetuximab and for TerSera to supply margetuximab for single patient use.
official title
An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol